Kenichi Harano

18PUBLICATIONS
190CO-AUTHORS
Predictive and prognostic markersGeriatrics and gerontologyCancer therapy (excl. chemotherapy and radiation therapy)Palliative careToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Sep 17, 2026
Changes and clinical impact of HER3 and ERBB3 expression in primary and recurrent ovarian cancer.

|Aug 07, 2026
cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer.

|Jul 30, 2026
Neoadjuvant olaparib and pembrolizumab combination therapy in the treatment of patients with HRD-positive advanced ovarian cancer: A pilot study.

|Jul 25, 2026
Outcome of advanced ovarian cancer patients who do not undergo cytoreductive surgery in the era of PARP inhibitors maintenance therapy: a propensity score-based analysis.

|Jun 19, 2026
Nationwide survey of hereditary breast and ovarian cancer-related clinical practice in gynecologic oncology in Japan: a joint study by the Japan Society of Gynecologic Oncology (JSGO) and the Japan Society of Obstetrics and Gynecology (JSOG).

|Jul 01, 2025
Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial.

Kenichi Harano, Roldano Fossati, Beatriz Pardo

Pageof 3

Frequent Collaborators

10 joint publications

Kazuhiro Takehara

8 joint publications

Aikou Okamoto

6 joint publications

Hidemichi Watari

6 joint publications

Daisuke Aoki